Clinical trial
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate…
NCT00005857 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00005857 |
|---|---|
| Title | Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy |
| Official title | Randomized Phase II Trial of Herceptin (NSC 688097) and Weekly Docetaxel (NSC 628503) in Androgen-Independent (Horomone Refractory) Adenocarcinoma of the Prostate (CaP) |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, docetaxel |
| Start date | Aug 1, 2000 |
| Primary completion | Oct 1, 2002 |
| Completion | Oct 1, 2002 |
| First posted | Aug 29, 2003 |
| Last update posted | Oct 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: